Company: BNBX
Filing Date: 2025-11-04
Form Type: 424B5
Source: 0001104659-25-105958
Chunk: 54

Company: BNB PLUS CORP.
Filing Date: 2025-11-04
Form: 424B5
Chunk 54
---
DNA™, Linea™ COVID-19 Diagnostic Assay Kit, safeCircle COVID-19 testing and TR8 pharmacogenetic
testing. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement
or sponsorship of us by, any other companies. All trademarks, service marks and trade names included or incorporated by reference in this
prospectus are the property of the respective owners.

<div align='center'>6

USE OF PROCEEDS</div>

Except as otherwise provided in the applicable prospectus supplement,
we intend to use the net proceeds from the sale of the securities covered by this prospectus for general corporate purposes, which may
include, but is not limited to, working capital, capital expenditures, business development and research and development expenditures
and acquisitions of new technologies or businesses. The precise amount, use and timing of the application of such proceeds will depend
upon our funding requirements and the availability and cost of other capital. Additional information on the use of net proceeds from an
offering of securities covered by this prospectus may be set forth in the prospectus supplement relating to the specific offering.

<div align='center'>7

DIVIDEND POLICY</div>

We have never declared or paid any cash dividends on our common stock.
We do not anticipate paying any cash dividends to stockholders in the foreseeable future. In addition, any future determination to pay
cash dividends will be at the discretion of our board of directors and will be dependent upon our financial condition, results of operations,
capital requirements, and such other factors as our board of directors deem relevant.

<div align='center'>DESCRIPTIONS OF THE SECURITIES WE MAY OFFER</div>

The descriptions of the securities contained in this prospectus, together
with any applicable prospectus supplement, summarize all the material terms and provisions of the various types of securities that we
may offer. We will describe in the applicable prospectus supplement relating to a particular offering the specific terms of the securities
offered by that prospectus supplement. We will indicate in the applicable prospectus supplement if the terms of the securities differ
from the terms we have summarized below. We will also include in the prospectus supplement information, where applicable, regarding material
United States federal income tax considerations relating to the securities.

We may sell from time to time, in one or more offerings:

| ● | shares of our common stock;                                          |
| ● | shares of our preferred stock;                                       |
| ● | debt securities